---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-011470"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:14:40.233019+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xilio Q2 net loss $13.9M; initiates Phase 2 for XTX101 in MSS CRC

## Summary
- Net loss $13.9M in Q2 2024 vs $19.4M in Q2 2023; R&D expenses $11.2M.
- Cash and equivalents $74.9M at June 30, 2024 (up from $44.7M Dec 2023); runway into Q2 2025.
- Initiated Phase 2 trial of XTX101 + atezolizumab in MSS CRC; data expected Q4 2024.
- Phase 1B dose expansion for XTX301 started; Phase 1A dose escalation ongoing with no DLTs.
- Promoted Chris Frankenfield to CFO while continuing as COO.

## SEC filing metadata
- accession: 0001558370-24-011470
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837024011470/0001558370-24-011470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837024011470/xlo-20240808x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-011470
- JSON: https://secwatch.observer/filing/0001558370-24-011470.json
- Plain text: https://secwatch.observer/filing/0001558370-24-011470.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.